What’s the current market cap for Alkermes stock?

Alkermes (ALKS) has a market cap of $7.4bn as of June 16, 2026.

What is the P/E ratio for Alkermes stock?

The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 48.78 as of June 16, 2026.

Does Alkermes stock pay dividends?

No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Alkermes dividend payment date?

Alkermes (ALKS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alkermes?

Alkermes (ALKS) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Alkermes stock | $ALKS Share Price

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Ticker

$ALKS

Sector

Health

Primary listing

NASDAQ

Employees

2,050

Headquarters

Dublin, Ireland

Website

www.alkermes.com

Alkermes Metrics

BasicAdvanced

$7.4bn

48.78

$0.91

0.26

-

What the Analysts think about Alkermes

Analyst ratings (Buy, Hold, Sell) for Alkermes stock.

Alkermes Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Alkermes Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Alkermes News

AllArticlesVideos

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ETF Trends·5 days ago

Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears

MarketBeat·6 days ago

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Business Wire·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.